Kus Fatih, Sirvan Firat, Yildirim Hasan Cagri, Koc Ilgin, Guduk Naciye, Arik Zafer
Department of Medical Oncology, Faculty of Medicine, Hacettepe University, 06000 Ankara, Turkey.
Department of Internal Medicine, Faculty of Medicine, Hacettepe University, 06000 Ankara, Turkey.
J Clin Med. 2025 Jun 14;14(12):4239. doi: 10.3390/jcm14124239.
Advanced-stage epithelial ovarian cancer is associated with variable survival outcomes, despite standardized treatments. Identifying reliable and accessible prognostic markers is critical to guide clinical decision-making. : The aim of this study was to evaluate the prognostic significance of the modified Glasgow Prognostic Score (mGPS) in patients with FIGO stage III-IV epithelial ovarian cancer. : In this retrospective cohort study, 89 patients diagnosed between 2018 and 2023 were analyzed. The mGPS was calculated from pre-treatment serum C-reactive protein (CRP) and albumin levels. Overall survival (OS) was assessed using Kaplan-Meier and Cox regression analyses. : The median OS was 32.3 months. When stratified by mGPS categories, the 2-year survival rates were 94%, 75%, and 34% in the mGPS 0, 1, and 2 groups, respectively ( < 0.001). In the multivariate Cox proportional hazards model, both mGPS (HR = 1.85; 95% CI: 1.12-3.07; = 0.016) and ECOG performance status (HR = 1.67; 95% CI: 1.02-2.75; = 0.043) were identified as independent predictors of overall survival. : The mGPS is a simple, low-cost, and independently predictive tool for overall survival in advanced ovarian cancer. By capturing both systemic inflammation and nutritional status, it enhances risk stratification and may support individualized treatment planning. Prospective validation is warranted.
尽管采用了标准化治疗，但晚期上皮性卵巢癌的生存结果仍存在差异。识别可靠且易于获取的预后标志物对于指导临床决策至关重要。本研究的目的是评估改良格拉斯哥预后评分（mGPS）在国际妇产科联盟（FIGO）III-IV期上皮性卵巢癌患者中的预后意义。在这项回顾性队列研究中，分析了2018年至2023年间确诊的89例患者。mGPS根据治疗前血清C反应蛋白（CRP）和白蛋白水平计算得出。采用Kaplan-Meier法和Cox回归分析评估总生存期（OS）。中位OS为32.3个月。按mGPS类别分层时，mGPS 0、1和2组的2年生存率分别为94%、75%和34%（<0.001）。在多变量Cox比例风险模型中，mGPS（HR = 1.85；95%CI：1.12 - 3.07；P = 0.016）和美国东部肿瘤协作组（ECOG）体能状态（HR = 1.67；95%CI：1.02 - 2.75；P = 0.043）均被确定为总生存期的独立预测因素。mGPS是晚期卵巢癌总生存期的一种简单、低成本且具有独立预测性的工具。通过同时反映全身炎症和营养状况，它增强了风险分层，可能有助于个性化治疗方案的制定。有必要进行前瞻性验证。
